Clinical Trials in Tokushima, Tokushima
8 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Relapsed Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals410 enrolled159 locationsNCT05730036
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled284 locationsNCT06252649
Recruiting
Phase 1Phase 2
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
Amyotrophic Lateral Sclerosis(ALS)Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals42 enrolled16 locationsNCT06351592
Recruiting
Phase 3
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
Acute Heart Failure
Juntendo University444 enrolled69 locationsNCT05392764
Recruiting
Phase 1Phase 2
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Regeneron Pharmaceuticals387 enrolled40 locationsNCT03761108
Recruiting
Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer372 enrolled221 locationsNCT04879329
Recruiting
Phase 2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Ovarian NeoplasmsUterine Cervical NeoplasmsEndometrial Neoplasms+3 more
Yonsei University198 enrolled18 locationsNCT06023862
Recruiting
Phase 3
Phase III Trial of Stage I Ovarian Cancer After Surgery
Epithelial Ovarian Cancer
Japanese Gynecologic Oncology Group360 enrolled103 locationsNCT04063527